Disclosures: Janet Chu: Gilead Sciences, Inc.: Grant/Research Support, Nghiem Ha: Nothing to Disclose, Mandana Khalili: gilead sciences: Grant/Research Support, GSK pharmaceuticals: Consultant, Intercept pharmaceuticals: Grant/Research Support, Gilead Sciences Inc: Consultant, Max Goldman: Eli Lilly: Stock - publicly traded company, Novo Nordisk: Stock - publicly traded company, Eli Lilly: Stock - publicly traded company, Madrigal: Stock - publicly traded company, Bilal Hameed: Gilead: Grant/Research Support, Intercept: Grant/Research Support, Pliant: Grant/Research Support, Novo Nordisk: Grant/Research Support, Madrigal: Grant/Research Support, Salix: Grant/Research Support, Mallinckrodt: Advisor, Pleiogenix: Advisor, CLDF: Advisor, Gilead: Consultant, Pioneering Medicine VII Inc: Consultant, Surrozen: Consultant, Pleiogenix: Stock privately held company, Scholars In Medicine: Speaking and Teaching, Rena Fox: Nothing to Disclose 1152 DIFFERENTIAL PROGNOSIS AND IMPACTS OF CARDIOMETABOLIC RISK FACTORS AND ALCOHOL INTAKE IN MASLD AND METALD PATIENTS Young Chang JAE YOUNG JANG 1 Soung Won Jeong 1 , 1 Soonchunhyang University Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are distinct yet overlapping conditions that significantly impact liver disease progression and mortality
Metabolomics in Clinical Practice: Improving Diagnosis and Informing Management
One of skill in the art further understands that, in various embodiments, an "effective amount" can be contacted with cells or administered to a subject in a single dose or via the use of multiple doses
Antos, J
ACS Sustainable Chem Eng
